FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294867706> ?p ?o ?g. }

• W2294867706 abstract "Pancreatic cancer is the fourth largest cause of cancer death in the United States and Europe with over 100,000 deaths per year in Europe alone. The overall 5-year survival ranges from 2–7 % and has hardly improved over the last two decades. Approximately 15 % of all patients have resectable disease at diagnosis, and of those, only a subgroup has a resectable tumour at surgical exploration. Data from cohort studies have suggested that outcome can be improved by preoperative radiochemotherapy, but data from well-designed randomized studies are lacking. Our PREOPANC phase III trial aims to test the hypothesis that median overall survival of patients with resectable or borderline resectable pancreatic cancer can be improved with preoperative radiochemotherapy. The PREOPANC trial is a randomized, controlled, multicentric superiority trial, initiated by the Dutch Pancreatic Cancer Group. Patients with (borderline) resectable pancreatic cancer are randomized to A: direct explorative laparotomy or B: after negative diagnostic laparoscopy, preoperative radiochemotherapy, followed by explorative laparotomy. A hypofractionated radiation scheme of 15 fractions of 2.4 gray (Gy) is combined with a course of gemcitabine, 1,000 mg/m2/dose on days 1, 8 and 15, preceded and followed by a modified course of gemcitabine. The target volumes of radiation are delineated on a 4D CT scan, where at least 95 % of the prescribed dose of 36 Gy in 15 fractions should cover 98 % of the planning target volume. Standard adjuvant chemotherapy is administered in both treatment arms after resection (six cycles in arm A and four in arm B). In total, 244 patients will be randomized in 17 hospitals in the Netherlands. The primary endpoint is overall survival by intention to treat. Secondary endpoints are (R0) resection rate, disease-free survival, time to locoregional recurrence or distant metastases and perioperative complications. Secondary endpoints for the experimental arm are toxicity and radiologic and pathologic response. The PREOPANC trial is designed to investigate whether preoperative radiochemotherapy improves overall survival by means of increased (R0) resection rates in patients with resectable or borderline resectable pancreatic cancer. Trial open for accrual: 3 April 2013 The Netherlands National Trial Register – NTR3709 (8 November 2012) EU Clinical Trials Register – 2012-003181-40 (11 December 2012)" @default.
• W2294867706 created "2016-06-24" @default.
• W2294867706 creator A5002147373 @default.
• W2294867706 creator A5003973735 @default.
• W2294867706 creator A5006641161 @default.
• W2294867706 creator A5015416945 @default.
• W2294867706 creator A5018257538 @default.
• W2294867706 creator A5019680927 @default.
• W2294867706 creator A5020655761 @default.
• W2294867706 creator A5031137165 @default.
• W2294867706 creator A5033788401 @default.
• W2294867706 creator A5043134557 @default.
• W2294867706 creator A5043942519 @default.
• W2294867706 creator A5045353714 @default.
• W2294867706 creator A5048525603 @default.
• W2294867706 creator A5051056050 @default.
• W2294867706 creator A5052876669 @default.
• W2294867706 creator A5053820526 @default.
• W2294867706 creator A5064998999 @default.
• W2294867706 creator A5065098749 @default.
• W2294867706 creator A5071097528 @default.
• W2294867706 creator A5072899975 @default.
• W2294867706 creator A5074957985 @default.
• W2294867706 creator A5089913915 @default.
• W2294867706 creator A5090947916 @default.
• W2294867706 date "2016-03-09" @default.
• W2294867706 modified "2023-09-30" @default.
• W2294867706 title "Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial" @default.
• W2294867706 cites W1503013008 @default.
• W2294867706 cites W1583589401 @default.
• W2294867706 cites W1971005338 @default.
• W2294867706 cites W1994177577 @default.
• W2294867706 cites W2005919713 @default.
• W2294867706 cites W2010249718 @default.
• W2294867706 cites W2011312114 @default.
• W2294867706 cites W2021585783 @default.
• W2294867706 cites W2025722173 @default.
• W2294867706 cites W2031584923 @default.
• W2294867706 cites W2043301107 @default.
• W2294867706 cites W2044211072 @default.
• W2294867706 cites W2047318784 @default.
• W2294867706 cites W2050023459 @default.
• W2294867706 cites W2059020621 @default.
• W2294867706 cites W2061274398 @default.
• W2294867706 cites W2062980345 @default.
• W2294867706 cites W2063861784 @default.
• W2294867706 cites W2074391876 @default.
• W2294867706 cites W2079934168 @default.
• W2294867706 cites W2097421939 @default.
• W2294867706 cites W2101995865 @default.
• W2294867706 cites W2103510102 @default.
• W2294867706 cites W2107539963 @default.
• W2294867706 cites W2111314439 @default.
• W2294867706 cites W2113662908 @default.
• W2294867706 cites W2115812130 @default.
• W2294867706 cites W2117009632 @default.
• W2294867706 cites W2120362356 @default.
• W2294867706 cites W2128562119 @default.
• W2294867706 cites W2130871964 @default.
• W2294867706 cites W2139248078 @default.
• W2294867706 cites W2142514824 @default.
• W2294867706 cites W2147078650 @default.
• W2294867706 cites W2147904963 @default.
• W2294867706 cites W2149942294 @default.
• W2294867706 cites W2150881991 @default.
• W2294867706 cites W2164534118 @default.
• W2294867706 cites W2168942492 @default.
• W2294867706 cites W2172087239 @default.
• W2294867706 cites W4244578979 @default.
• W2294867706 cites W592682419 @default.
• W2294867706 doi "https://doi.org/10.1186/s13063-016-1262-z" @default.
• W2294867706 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4784417" @default.
• W2294867706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26955809" @default.
• W2294867706 hasPublicationYear "2016" @default.
• W2294867706 type Work @default.
• W2294867706 sameAs 2294867706 @default.
• W2294867706 citedByCount "126" @default.
• W2294867706 countsByYear W22948677062017 @default.
• W2294867706 countsByYear W22948677062018 @default.
• W2294867706 countsByYear W22948677062019 @default.
• W2294867706 countsByYear W22948677062020 @default.
• W2294867706 countsByYear W22948677062021 @default.
• W2294867706 countsByYear W22948677062022 @default.
• W2294867706 countsByYear W22948677062023 @default.
• W2294867706 crossrefType "journal-article" @default.
• W2294867706 hasAuthorship W2294867706A5002147373 @default.
• W2294867706 hasAuthorship W2294867706A5003973735 @default.
• W2294867706 hasAuthorship W2294867706A5006641161 @default.
• W2294867706 hasAuthorship W2294867706A5015416945 @default.
• W2294867706 hasAuthorship W2294867706A5018257538 @default.
• W2294867706 hasAuthorship W2294867706A5019680927 @default.
• W2294867706 hasAuthorship W2294867706A5020655761 @default.
• W2294867706 hasAuthorship W2294867706A5031137165 @default.
• W2294867706 hasAuthorship W2294867706A5033788401 @default.
• W2294867706 hasAuthorship W2294867706A5043134557 @default.
• W2294867706 hasAuthorship W2294867706A5043942519 @default.
• W2294867706 hasAuthorship W2294867706A5045353714 @default.
• W2294867706 hasAuthorship W2294867706A5048525603 @default.
• W2294867706 hasAuthorship W2294867706A5051056050 @default.
• W2294867706 hasAuthorship W2294867706A5052876669 @default.

• next